Form Type: 4

SEC EDGAR Link
Accession Number:0001140361-21-032105
Date:2021-09-20
Issuer: BROOKLYN IMMUNOTHERAPEUTICS, INC. (BTX)
Original Submission Date:

Reporting Person:

SIDHU ROGER
C/O BROOKLYN IMMUNOTHERAPEUTICS, INC.
140 58TH STREET, BUILDING A, SUITE 2100 BROOKLYN, NY 11220

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION 9.96 2021-09-20 deemed execution date A 161,300 (a) 2031-09-20 common stock 161,300 $9.96 161,300 direct
RESTRICTED STOCK UNIT 0.0 2021-09-20 deemed execution date A 80,650 (a) 2031-09-20 common stock 80,650 $0.00 80,650 direct
Footnotes
IDfootnote
f1 the option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on september 20, 2022, and 1/36 of the remaining shares covered thereby vesting on the twentieth day of each calendar month from october 2022 through september 20, 2025, subject to continued service through each vesting date.
f2 each restricted stock unit represents a contingent right to receive one share of common stock.
f3 the rsu grant vests and becomes exercisable in four equal installments on september 20 of each of 2022, 2023, 2024 and 2025, provided that it shall vest in full immediately prior to a change in control (as defined in dr. sidhu's executive employment agreement, effective september 20, 2021), subject to continued service through each vesting date.

Elevate your investments